In this episode, Parexel Executive Vice President and Chief Commercial & Strategy Officer Peyton Howell interviews Meghan FitzGerald, Parexel Board Advisor and author of the new book Ascending Davos: A Career Journey from the Emergency Room to the Boardroom. The two healthcare leaders discuss topics including Meghan’s career pivots from nursing to the healthcare industry to private equity, why you should take your CFO to lunch, and their unexpected friendship.
Episode 6: The opportunity for biotechs in precision medicine: driving value and bringing important new therapies to patients
Within the past 20 years, the field of precision medicine has been transformed. For biotech companies, this new landscape holds tremendous promise for innovation. So, why aren’t more companies leveraging this approach? In this episode, Parexel precision medicine experts Angela Qu and Arlene Hughes join host Alberto Grignolo to discuss this conundrum, and what biotechs should be thinking about right from the start, to open up the opportunity for this approach to help bring innovation and new therapies to more patients.
In this episode, Doug Olson, one of the first CAR-T patients treated on a clinical trial for CLL almost 10 years ago, details his experiences with this therapy in its earliest days. Parexel’s experts Mo Heidaran, Alexander Gee and host Alberto Grignolo, all part of our newly-integrated Regulatory & Access consulting unit, also weigh in on the current regulatory and reimbursement landscape for CAR-T and what we might look forward to in the future for this and other cell and gene therapies.
In this episode Alberto Grignolo, Corporate Vice President, Parexel, Sy Pretorius, Executive Vice President and Chief Medical and Scientific Officer, Parexel, and Roz Round, Director of Parexel's Patient Innovation Center, team up to discuss how the clinical research industry can bridge the gap between the scientific needs of research and development and the needs of patients. Stemming from feedback based on a survey looking at perceptions of clinical trials, the episode explores current barriers to clinical trial participation patients face, how we can make research more patient-centric, and techniques to adopt to increase patient-centricity. Later, Roz interviews Shannon Scarlett, a Parexel employee and cancer survivor, about her experience as a trial participant.
Recorded during the 2019 World Orphan Drug Congress, this episode brings together Amy McKee and Mo Heidaran who both recently joined PAREXEL from the FDA, as well as Zizi Imatorbhebhe, an expert in rare disease drug development. Amy, Mo and Zizi discuss how the industry can work to deliver more innovative treatments for rare disease patients and the reality of working with the Food and Drug Administration (FDA). In the first segment, the experts share their insights working with the rare disease/orphan drug community, including patients, physicians, regulators and patient advocacy groups. Next, they focus on FDA’s recent leadership change and tackle some common misconceptions about working with the Agency.
In our inaugural podcast, Siri Chilazi, a gender equality expert and Harvard Kennedy School Research Fellow, speaks with female leaders from PAREXEL - Dr. Kemi Olugemo, Dr. Ubavka DeNoble, Aida Sabo, and Peyton Howell - in celebration of International Women’s Day. They discuss what it means to be a female leader in a STEM field and what challenges they have faced throughout their journeys, with the hope that their stories and lessons learned will inspire other young women currently rising through the ranks. They also dive into how their experiences at PAREXEL have influenced their leadership, and what the 2019 International Women’s Day motto of “Balance for Better” means to them.